Schedule 13G ownership disclosure

BRIDGEBIO PHARMA INC

Common Stock, par value $0.001 per share (the "Shares") · CUSIP: 10806X102

Event date: 2026-09-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Farallon Capital Management, L.L.C.

    Shares: 14,247,000 · Class: 7.3%

  • Dapice Joshua J.

    Shares: 14,247,000 · Class: 7.3%

  • Dreyfuss, Philip D.

    Shares: 14,247,000 · Class: 7.3%

  • Dunn Hannah E.

    Shares: 14,247,000 · Class: 7.3%

  • Gehani, Varun N.

    Shares: 14,247,000 · Class: 7.3%

  • Giauque, Nicolas

    Shares: 14,247,000 · Class: 7.3%

  • Husen, Avner A.

    Shares: 14,247,000 · Class: 7.3%

  • Kim, David T.

    Shares: 14,247,000 · Class: 7.3%

  • Linn, Michael G.

    Shares: 14,247,000 · Class: 7.3%

  • Luo Patrick (Cheng)

    Shares: 14,247,000 · Class: 7.3%

  • Roberts, Jr., Thomas G.

    Shares: 14,247,000 · Class: 7.3%

  • Saito Edric C.

    Shares: 14,247,000 · Class: 7.3%

  • Short Daniel S.

    Shares: 14,247,000 · Class: 7.3%

  • Spokes, Andrew J. M.

    Shares: 14,247,000 · Class: 7.3%

  • Warren, John R.

    Shares: 14,247,000 · Class: 7.3%

  • Wehrly, Mark C.

    Shares: 14,247,000 · Class: 7.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000908834-26-000518
Form type
SCHEDULE 13G/A
Filer
BridgeBio Pharma, Inc.
CIK
CIK 1743881
Filed
Nov 12, 2026
Reporting period
Sep 30, 2026
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub